The company has not filed an annual or quarterly report since its FY2022 10-K, filed Mar 20, 2023. Its latest SEC filing is a SC 13D/A from Oct 18, 2023.
10-K for FY2022, filed Mar 20, 2023
The sections below describe the company as of the FY2022 annual report.
Develops NKT cell therapies and other cancer drug candidates, licenses drug rights to pharmaceutical companies, and distributes specialty medicines to wholesalers.
10-K for FY2022, filed Mar 20, 2023We are developing autologous and allogeneic, or “off-the-shelf”, NKT cell immunotherapies for the treatment of solid tumors and…View ↗
The Company out-licenses certain of its IP to other pharmaceutical companies in specific territories that allow the customer to use…View ↗
Commercial Platform— This operating segment includes APD, which focuses on the distribution, and sales of specialty pharmaceuticals. This…View ↗
The Company’s Commercial Platform generates revenue by distributing specialty products through independent pharmaceutical wholesalers. The…View ↗
Drug companies pay for rights to use licensed drug IP, with upfront fees and milestone payments when development or sales goals are reached, plus royalties as licensed products sell. Athenex also distributes specialty medicines through independent pharmaceutical wholesalers.
10-K for FY2022, filed Mar 20, 2023The Company out-licenses certain of its IP to other pharmaceutical companies in specific territories that allow the customer to use…View ↗
Certain out-license agreements include performance obligations to manufacture and provide drug product in the future for commercial sale…View ↗
The Company’s Commercial Platform generates revenue by distributing specialty products through independent pharmaceutical wholesalers. The…View ↗
$102.8M
10-K for FY2022, filed Mar 20, 2023
$102.8M ↗
Pharmaceutical companies can license Athenex's drug rights. For specialty medicines, Athenex sells through independent pharmaceutical wholesalers, which resell to hospitals, other health facilities and independent pharmacies.
10-K for FY2022, filed Mar 20, 2023
No. It lost $103.4M in FY2022.
10-K for FY2022, filed Mar 20, 2023
8-K, filed Oct 2, 2023
As previously disclosed, on May 14, 2023, Athenex, Inc. (the “Company”) together with certain of its subsidiaries (collectively, the…View ↗
8-K, filed Aug 17, 2023
On August 11, 2023, Joe Annoni, Chief Financial Officer and Assistant Chief Restructuring Officer of Athenex, Inc. (the “Company”), and the…View ↗
8-K, filed Jul 18, 2023
On June 6, 2023, the Company and Athenex R&D LLC, one of the Debtors and a subsidiary of the Company, entered into an asset purchase…View ↗
8-K, filed May 22, 2023
On May 14, 2023 (the “Petition Date”), Athenex, Inc. (the “Company”) together with certain of its subsidiaries (collectively, the…View ↗
Grew. Revenue grew 15% in 4 years, from $89.1M in FY2018 to $102.8M in FY2022, about 4% a year.
Cell therapy focus
The earlier report described several oncology technologies, including Orascovery, Src kinase, TCR-T and arginine deprivation. The latest report centers development on NKT cell therapies while continuing selected Oral Paclitaxel studies.
10-K for FY2019, filed Mar 2, 2020 10-K for FY2022, filed Mar 20, 2023Athenex, Inc., together with its subsidiaries (“Athenex,” the “Company,” “we,” “us” or “our”), is a global biopharmaceutical company…View ↗
In 2023, we plan to focus on developing our novel immune effector cell therapy platform and its product candidates. See “Our R&D Programs –…View ↗
In early 2022, we announced a new vision for the future of Athenex that is focused on the cell therapy platform. We redirected our research…View ↗
We are developing autologous and allogeneic, or “off-the-shelf”, NKT cell immunotherapies for the treatment of solid tumors and…View ↗
Supply-chain operations
The earlier report described a Global Supply Chain Platform alongside oncology and commercial operations; the latest report describes only the Oncology Innovation and Commercial platforms, after supply-chain components were sold or discontinued.
10-K for FY2019, filed Mar 2, 2020 10-K for FY2022, filed Mar 20, 2023Athenex, Inc., together with its subsidiaries (“Athenex,” the “Company,” “we,” “us” or “our”), is a global biopharmaceutical company…View ↗
We manage our operations and allocate resources in line with our two distinct reportable segments: (1) our Oncology Innovation Platform…View ↗
Competes with Adicet Bio, Allogene Therapeutics, Appia Bio, Arovella Therapeutics, Atara Bio, Autolus, BrightPath Biotherapeutics, Caribou Biosciences, Cellectis, Celyad, Century Therapeutics, Crispr Therapeutics, Cytovia Therapeutics, Editas Medicine, Fate Therapeutics, GammaDelta Therapeutics, Immatics, In8bio, Kiromic, and Lava Therapeutics
10-K for FY2022, filed Mar 20, 2023The biopharmaceutical industry and the oncology subsector are characterized by rapid evolution of technologies, fierce competition, and…View ↗
Loading...
